Pci-1714 pdf

PCI data acquisition card. Evaluate the quality of the search results:. Your suggestions for improvement:. Please specify: Help us improve: remaining Send. Your answer has been taken into account. Thank-you for your help. Subscribe to our newsletter. Skip to main content. This browser is no longer supported. Download Microsoft Edge More info.

Contents Exit focus mode. Please rate your experience Yes No. Any additional feedback? Submit and view feedback for This product This page. View all page feedback.

In this article. Register Log In. Case Study. Product A-Z. Featured Topics Industry 4. Advantech Global Services. Design To Order Services. Channel Partners. Downloads Resource Check your products information. Find articles by Halil Ibrahim Biter. Find articles by Ibrahim Oguz Karaca. Find articles by Erdal Belen. Find articles by Mehmet Mustafa Can. Victor Serebruany, Academic Editor. Author information Article notes Copyright and License information Disclaimer.

Received Mar 25; Accepted May Associated Data Data Availability Statement The data presented in this study are available on request from the corresponding author.

Abstract Ticagrelor is believed to be a more potent and faster antiplatelet agent compared with clopidogrel and may result in lower ischemic outcomes in patients with acute coronary syndrome. Keywords: switching protocols, coronary artery disease, de-escalation, unstable angina, antiplatelet agent, vascular disease.

Open in a separate window. Figure 1. Materials and Methods The present study was a retrospective cohort study conducted in two centers in Istanbul, Turkey.

Study Endpoints The primary outcome was a composite of an efficacy endpoint [major adverse cardiac and cerebrovascular events MACCEs defined as a composite of cardiovascular death, recurrent myocardial infarction, target vessel revascularization, and non-fatal stroke one month follow up. Table 1 Baseline characteristics of the study population.

Figure 2. Table 2 Study outcomes. Discussion Contrary to the traditional concept, our study indicated no advantage of clopidogrel mg LD over mg LD during switching from ticagrelor. Author Contributions Conceptualization, B.

Funding This research received no external funding. Institutional Review Board Statement The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee E Informed Consent Statement Informed consent was obtained from all subjects involved in the study. Data Availability Statement The data presented in this study are available on request from the corresponding author. Conflicts of Interest The authors declare no conflict of interest.

References 1. Sun J. Shuldiner A. Association of cytochrome P 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. Wallentin L. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. Cannon C. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes PLATO : A randomised double-blind study.

Valgimigli M. Heart J. Storey R. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Angiolillo D.